GlaxoSmithKline is a guide to all bribers

GlaxoSmithKline (China) Investment Co., Ltd. is suspected of commercial bribery and four Chinese executives are detained. One British executive who has left the country is also likely to be involved in the case. A total of more than 20 drug companies and travel agency staff were registered for investigation. This is the case in which the most serious multinational companies are suspected of commercial bribery in China in recent years. Its detection marks a major step forward in China’s anti-corruption campaign.

Some foreign media questioned China’s “shrinking” of the investment environment for foreign investment, and the foreign media complained that GlaxoSmithKline’s performance in other countries was “very good,” but it was “learned” in China, proving that China is a “big” country. Dyeing cylinder." These voices have certain meaning for foreign companies in China in violation of business ethics and even criminal defense.

However, the resolute action by the Chinese public security department is the best answer to these noises. There is no reason for crimes, and the “abundance” of transnational corporations abroad cannot bring them immunity from criminal law in China. On the 15th, GlaxoSmithKline apologized to the Chinese public on bribery. The justness of criminal investigations demonstrated its solidity.

The investment of multinational corporations has contributed to boosting China’s economic development. Foreign investors have also enjoyed many preferential treatments throughout China. The overall impression that foreign capital has left for the Chinese community should be said to be good. Local governments are still competing for the introduction of important multinational corporations. The overall attitude of the state and local governments to foreign capital is very stable, there is no sudden change, and there is no incentive to do so.

However, anti-commercial bribery is another matter. It is part of China’s anti-corruption business and can only have one standard. It must be pointed out that the commercial bribery of some foreign-funded companies in China is very serious and it is almost blatant. They have destroyed business ethics and undermined China’s economic order. It is only a matter of time before problems arise.

GlaxoSmithKline spends a large amount of “public relations fee” to pay bribes in the middle of the sale of drugs is almost semi-public, and it is not surprising that China’s anti-corruption storm opened its lid.

In recent years, anti-corruption has mainly dealt with bribery parties. Corrupt officials have always been the focus of the public. At least in public opinion, the bribery party has been ignored. Sometimes they even get an understanding and sympathy, as if they were the victims of official greed.

Its implementation of bribery is also a violation of the law and one of the most difficult enemies of legal construction. Not all bribers are "forced." Many bribers regard this as their "main means" for business, as a quick way to extract unjust high profits. They have disrupted legitimate commercial competition and forcibly converted evil scams into "hidden rules." They are fueling the spread of corruption.

Combating bribery should be one of the highlights of anti-corruption. This will greatly curb the level of corruption and play a role in wage collection. The bribers and corrupt officials must fight from both sides at the same time, and the effect must be doubled.

China had also paid bribery in the past, but the high-level multinational corporations in China were almost "one-pot" for the first time. We hope that this time the legal investigation can be made resolutely and thoroughly, and it will shock those who have bad ideas to kill chickens and monkeys.

Because anti-corruption has touched multinational corporations, some foreign media have talked about bleak and implicated China’s foreign investment policy. This is a morally low self-defining performance. They should take the whip to GlaxoSmithKline and pump it to some foreign companies that dare to do anything for commercial interests in China.

China is advancing step by step in a clean and honest society. Although it is struggling, it will never back off. GlaxoSmithKline should become a reference to all Chinese and foreign companies in China. The risk of corruption will increase sharply, and the risk of bribery will surely increase. We believe that the reporting and disclosure of bribery will gradually embark on a new platform such as the Internet. Supervision of bribery will become ubiquitous sooner or later.